Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Ribavirin may reduce use of clotting factors in hemophilia and Hep C

Findings based on case series in this week's issue of JAMA, show that ribavirin in combination with interferon, and possibly alone, may reduce the use of clotting factors in patients with hemophilia and chronic Hepatitis C.

News image

fiogf49gjkf04

Ribavirin has been used in combination with interferon-alfa to treat chronic Hepatitis C.

This combination therapy has been reported to be more effective than interferon monotherapy for eradicating Hepatitis C virus, including that occurring in patients with concomitant hemophilia.

Dr Takamatsu and colleagues from Japan aimed to assess the reduction in the use of clotting factors in Hepatitis C-positive patients with hemophilia treated with ribavirin and interferon.

The researchers treated 8 consecutive patients with hemophilia as outpatients for Hepatitis C infection with interferon and ribavirin between June 2002 and November 2003 at Nagoya University Hospital.

The team reported that all patients were men with a mean age of 45 years of which 6 patients had hemophilia A, and 2 had hemophilia B.

The mean use of clotting factors per month during treatment and after treatment lower than before treatment
JAMA

Hemophilia was severe in 3 patients, moderate in 2, and mild in 3 whilst 4 patients had been previously treated with interferon alfa-2b alone, but Hepatitis C virus had not been eradicated.

The investigators compared the average use of clotting factors from the 5 patients with moderate and severe hemophilia before, during, and after treatment.

Oral ribavirin was administered by the researchers at a dose of 600 mg/d for patients who weighed 60 kg or less and 800 mg/d for those who weighed more than 60 kg during 24 weeks.

The research team reduced the dose of ribavirin by 200 mg/d if the patient’s hemoglobin concentration decreased to below 10 g/dL due to hemolytic anemia induced by ribavirin; the hemoglobin level did not fall this low from any other causes.

In the 5 patients requiring clotting factor, the mean use of clotting factors per month for the 6 months prior to combination therapy was 3783 U/mo.

During therapy, the mean use of clotting factors per month was 1605 U/mo; and for the 6 months after therapy it was 1667 U/mo.

The researchers concluded that the mean use of clotting factors per month during treatment and after treatment lower than before treatment.

Dr Takamatsu concludes, “Based on this case series, ribavirin in combination with IFN, and possibly alone, may reduce the use of clotting factors in patients with hemophilia and chronic hepatitis C.”

“Further studies, including replication of these findings and clinical trials, would help to clarify the potential role of ribavirin in these patients.”

JAMA 2005: 293(10): 1190-1192
11 March 2005

Go to top of page Email this page Email this page to a colleague

 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us